. 2019 Apr 11;8(5):R91–R104. doi: 10.1530/EC-19-0114
This work is licensed under a Table 2.
Drugs that positively increased the ACC apoptosis rate in in vitro and in vivo studies.
| Anti-ACC drugs | Drug type | Method to evaluate apoptosis | Samples type | Ref. |
|---|---|---|---|---|
| AMG 900 | Aurora kinase inhibitor | Annexin V-FITC apoptosis detection assay | ACC cell line NCI-H295 | (141) |
| ATR-101 (PD132301-02) | Adrenalytic activity inhibitor | TUNEL assay | NCI-H295R xenographs | (142) |
| Annexin V-FITC apoptosis detection assay | ACC cell line NCI-H295R | |||
| Cholesterol free sHDL nanoparticles in combination with cisplatin, etoposide or mitotane | efflux cholesterol inducer | Annexin V-FITC apoptosis detection assay | ACC cell lines: SW-13 and NCI-H295R | (143) |
| Docosahexenoic acid | n-3 polyunsaturated fatty acid/mTOR complex 1/2 inhibitor | Annexin V-FITC Apoptosis Detection assay | ACC cell lines: SW-13 and NCI-H295R | (144) |
| TUNEL assay | SW-13 xenographs | |||
| DZNep | EZH2 (histone modifier) inhibitor | BCL2, BCL-XL and BIRC5 expression/Caspase 3 activity assay/TUNEL assay | ACC cell line NCI-H295R | (145) |
| Erlotinib and NVP-AEW541 combination | EGFR and IGF1R inhibitor | Annexin V-FITC apoptosis detection assay | ACC cell lines: SW-13 and NCI-H295R | (134) |
| Fingolimod (FTY720) | Sphingosine kinase 1 antagonist | Annexin V-FITC apoptosis detection assay | ACC cell lines: SW-13 and NCI-H295R | (146) |
| G-1 | Non-steroidal G protein-coupled estrogen receptor agonist | Annexin V-FITC Apoptosis Detection assay/Caspase 9 and 3/7 activity assay/TUNEL assay | ACC cell line NCI-H295R | (147) |
| Metformin | Biguanide cationic agent | Annexin V Apoptosis Detection assay/Bcl-xl, Bcl-2, Bcl-w and Cleaved Caspase 3 expression | ACC cell line NCI-H295R | (148) |
| Mitotane (drug used in ACC patients) | Steroidogenesis inhibitor and cytostatic antineoplastic | Annexin V Apoptosis Detection assay/Bax, Bak and Bcl-2 expression | ACC cell line NCI-H295 | (149, 150) |
| Caspase 3/7 activity assay | ACC cell line NCI-H295R | (151) | ||
| Niclosamide | Anti-helminthic agent | Caspase 3/7 activity assay | ACC cell lines: BD140A, SW-13 and NCI-H295R | (152) |
| Rapamycin | mTOR complex 1 inhibitor | Cleaved Caspase 3 expression | Adrenocortical tumors from AdTAg mice | (153) |
| Rottlerin | Anti-helminthic or fertilization antagonist | TUNEL assay | SW-13 xenographs | (133) |
| Annexin V-FITC Apoptosis Detection assay | ACC cell lines: SW-13 and NCI-H295R |
ACC, adrenocortical carcinomas; AMG, urora kinases inhibitor; Bak, B-cell lymphoma 2 homologous antagonist/killer; Bax, B-cell lymphoma 2-associated X protein; BCL-2, B-cell lymphoma 2; BCL-W, B-cell lymphoma-like 2; BCL-XL, B-cell lymphoma-extra-large; BIRC5, Baculoviral IAP repeat containing 5; DZNep, Deazaneplanocin A; EGFR, epidermal growth factor receptor; EZH2, enhancer of zeste homolog 2; FITC, fluorescein isothiocyanate; IGFR, insulin growth factor receptor; mTOR, mammalian target of rapamycin; NCI, National Cancer Institute; sHDL, synthetic high-density lipoprotein; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.